Introduction {#sec1}
============

Our knowledge about the complexity of posttranscriptional control of gene expression is continuously expanding due to findings of new effectors of mRNA splicing, stability, and translation, as well as the discovery of the large extent of posttranscriptional regulation of noncoding RNAs. Several examples of nuclear and cytoplasmic control of miRNA maturation have been described ([@bib11; @bib34; @bib6]). More recently, with the discovery of a huge number of long noncoding RNAs (lncRNAs), the repertoire of mechanisms that control RNA biogenesis is expected to expand even further.

lncRNAs have been implicated in a large number of transcription regulatory processes ([@bib25]). Moreover, they have been shown to take part in posttranscriptional events such as stability and translational control of mRNAs ([@bib10; @bib30; @bib33]), as well as sponging activity for miRNAs ([@bib24; @bib5; @bib31; @bib14]). The latter activity suggests that coding and noncoding RNAs may be part of common regulatory circuitries in which they can control one another through their ability to compete for miRNA binding, suggesting the term "competing endogenous RNA" (ceRNA; [@bib26]).

Linc-MD1 was the first lncRNA to be shown to play a relevant role in muscle differentiation by regulating specific myogenic factors required for the onset of late muscle gene transcription. In the cytoplasm, linc-MD1 was shown to act as a ceRNA for miR-135 and miR-133 ([@bib5]). By this mode of action, linc-MD1 impacts the distribution of these miRNAs on their natural mRNA targets, imposing an additional level of posttranscriptional control. Maml1 and Mef2C, two relevant factors in activating late muscle gene expression, were identified as natural targets of miR-133 and miR-135, which in turn are controlled by the "sponge" activity of linc-MD1. Given this tripartite regulatory network (mRNA, miRNA, and lncRNA), it is expected that a number of different factors that share target sites for common miRNAs could belong to the same circuitry.

Another interesting aspect of linc-MD1 relates to its biogenesis. Since it harbors the pri-miR-133b sequence, it can act alternatively as a miRNA precursor, if Drosha cleaves it in the nucleus, or as a sponge for the encoded miR-133b, if it is exported to the cytoplasm as an unprocessed species. Therefore, a major point related to how the alternative fate of the linc-MD1 primary transcripts is controlled awaited clarification.

With the aim of identifying members of the linc-MD1-regulated network, we found an additional component of this circuitry, the HuR protein, which is already known for its crucial role in myogenesis ([@bib29]).

This protein, which is known to interact with a large number of RNA substrates ([@bib19; @bib23]), was initially described as an adaptor for mRNA export ([@bib9]) and subsequently was reported to have a stabilizing effect on several important myogenic factors, such as MyoD, myogenin, and p21 ([@bib8]). Over the past few years, evidence has also accumulated regarding its cooperative ([@bib16]) and competitive ([@bib17]) interplay with miRNAs in controlling translation and stability of specific mRNAs. More recently, other contributions pointed to the role of HuR in controlling the processing and stability of pri-miRNAs ([@bib6]) and lncRNAs ([@bib33]).

In this paper, we describe that HuR is negatively controlled by miR-133, and that linc-MD1, through miR-133 sponging, positively controls HuR levels during early stages of muscle differentiation. In turn, HuR controls linc-MD1 by favoring its accumulation in the cytoplasm at the expense of miR-133b synthesis. Finally, we show that HuR is also required in the cytoplasm to ensure efficient lincMD1 sponge activity by facilitating miRNA recruitment. Altogether, these data show the existence of a specific circuitry in which the timely controlled expression of linc-MD1 and HuR is reciprocally regulated in order to establish correct progression of in vitro muscle differentiation.

Results {#sec2}
=======

HuR Expression Is Sustained by the miR-133 Decoy Activity of linc-MD1 {#sec2.1}
---------------------------------------------------------------------

In order to expand the collection of possible linc-MD1-ceRNA interactions, we performed in silico analysis of miR-133 and miR-135 target predictions and searched for putative targets involved in muscle differentiation. Putative targets were predicted using the miRanda algorithm ([@bib7]). The list of all putative target mRNAs was then filtered for expression in skeletal muscle according to the Gene Expression Barcode data set ([@bib20]). Among the top 20 predictions of each miRNA ([Table S1](#app2){ref-type="sec"} available online), the miR-133 putative target HuR was selected for further validation due to its well-described role in muscle differentiation ([@bib29]; see [Figure S1](#app2){ref-type="sec"}A). The HuR locus is known to give rise to different transcripts due to the usage of alternative polyadenylation sites ([@bib1]). Therefore, before validating it as a miR-133 target, we checked the isoforms expressed in the murine myogenic C~2~C~12~ cell line by using RNA sequencing (RNA-seq) data (V. Cazzella, personal communication). We found that the major species contains one putative miR-133 responsive element (133-MRE), whereas a second, less abundant species, with an extended 3′ UTR, contains two 133-MREs.

Luciferase constructs carrying the 3′ UTR sequence of HuR corresponding to the short and long isoforms (short and long Luc-HuR wild-type \[Luc-HuR*WT*\]; [Figure 1](#fig1){ref-type="fig"}A), together with derivatives depleted of the miR-133 sites (short and long Luc-HuR*mut*), were used to assess the responsiveness to the miR-133/linc-MD1 circuitry. [Figure 1](#fig1){ref-type="fig"}B shows that in C~2~C~12~ cells, locked nucleic acid (LNA) oligos against miR-133 derepress the luciferase activity of both the short and long Luc-HuR*WT* constructs. In line with this, the luciferase levels of the Luc-HuR*WT* constructs increased when linc-MD1, which is known to sponge miR-133, was cotransfected ([Figure 1](#fig1){ref-type="fig"}C, pMD1). This effect was stronger with the long Luc-HuR*WT*, which has two 133-MREs. No derepression of luciferase activity was observed when a linc-MD1 construct depleted of the miR-133 binding site was cotransfected ([Figure 1](#fig1){ref-type="fig"}C, pMD1Δ133). As control, the short and long Luc-HuR*mut* constructs did not show any sensitivity to linc-MD1.

The same responsiveness to miR-133 was observed in nonmyogenic cells, such as HeLa cells in which miR-133 was produced from a transfected plasmid ([Figure S1](#app2){ref-type="sec"}B).

In order to validate the crosstalk between HuR and linc-MD1 through competition for miR-133 ([Figure 1](#fig1){ref-type="fig"}D), we measured endogenous HuR levels upon RNAi or overexpression of linc-MD1 in C~2~C~12~ cells. [Figure 1](#fig1){ref-type="fig"}E shows that HuR decreased when linc-MD1 was downregulated, and increased when linc-MD1 was overexpressed. In C~2~C~12~ cells treated with anti-miR-133 LNA oligonucleotides, HuR increased similarly to cells overexpressing linc-MD1.

These results show that miR-133 controls HuR and that this repressing activity is modulated by linc-MD1, indicating that, similarly to Maml1 ([@bib5]), HuR also participates in the crosstalk with the lncRNA through competition for miR-133.

HuR Physically Interacts with linc-MD1 {#sec2.2}
--------------------------------------

In order to analyze the interaction between linc-MD1 and the RNA-binding protein HuR, we performed RNA immunoprecipitation (RIP) assays with anti-HuR antibodies and isotype-matched immunoglobulin G (IgG). The IP specificity was tested by western blot ([Figure S2](#app2){ref-type="sec"}A). [Figure 2](#fig2){ref-type="fig"}A shows that, similarly to MyoD mRNA ([@bib8]), linc-MD1 coimmunoprecipitates with HuR. Notably, in the IP RNA fraction, miR-133 and miR-135 were also found ([Figure S2](#app2){ref-type="sec"}B). The interaction of HuR with linc-MD1 appears to be evolutionarily conserved, since the human counterpart of linc-MD1, linc-hMD1 ([@bib28]), was also detected in HuR-IPs in human myoblasts ([Figure 2](#fig2){ref-type="fig"}A, lower panel). In line with its ability to bind miRNAs, linc-MD1 was also found in Ago2 immunoprecipitates ([Figures 2](#fig2){ref-type="fig"}B and [S2](#app2){ref-type="sec"}C).

These interactions were also tested by a parallel approach in which C~2~C~12~ cell extracts were loaded on streptavidin columns prebound with biotinylated antisense RNAs complementary to linc-MD1 ([Figure 2](#fig2){ref-type="fig"}C, top). HuR and Ago were specifically recovered from the fraction bound to the MD1 probe together with linc-MD1 ([Figure S2](#app2){ref-type="sec"}E), miR-133, and miR-135 ([Figure 2](#fig2){ref-type="fig"}C, bottom). A biotinylated control RNA complementary to the multiple cloning site of pCDNA3.1 vector was used as control ([Figures 2](#fig2){ref-type="fig"}C and [S2](#app2){ref-type="sec"}D). These results demonstrate that HuR binds linc-MD1, and confirm linc-MD1's ability to interact in vivo with both miR-133 and miR-135, associated with the Ago protein. The absence of any pull-down species in growth medium (GM), where linc-MD1 is not expressed ([Figure S2](#app2){ref-type="sec"}E, right panel), confirms the specificity of the interaction observed in differentiation medium (DM).

In order to further analyze the direct interaction with HuR, we performed electrophoretic mobility shift analysis (EMSA) with a Flag-HuR protein purified from C~2~C~12~ cells ([Figure S2](#app2){ref-type="sec"}F) incubated with different portions of in vitro transcribed, P^32^-labeled linc-MD1 ([Figure 2](#fig2){ref-type="fig"}D). With respect to the high affinity of the MyoD mRNA binding site (MYOD lanes), a lower but specific interaction with the pri-miR133-containing region (MD1-133b lanes) of linc-MD1 was detected. The specificity of this interaction was verified by competition with specific and unspecific RNAs (MD1-133b and tRNA; [Figure 2](#fig2){ref-type="fig"}E). Moreover, a mutation of the sequence AAUAUUU, which is located at the base of the pri-miR-133b stem-loop region and was identified by PARCLIP analysis in [@bib19]) as one of the most common HuR-binding sites, produced a strong decrease in HuR binding when compared with the WT counterpart ([Figure 2](#fig2){ref-type="fig"}F).

HuR Controls the Balance between linc-MD1 and miR-133 Biogenesis {#sec2.3}
----------------------------------------------------------------

HuR was previously described to have a peculiar nuclear/cytoplasmic distribution during muscle differentiation and to be involved in shuttling RNA from these two compartments ([@bib29]). In early phases of C~2~C~12~ differentiation, HuR is predominantly nuclear ([Figure S3](#app2){ref-type="sec"}A). Western analysis indicated that it peaks at 48 hr after induction to differentiation, and decreases after 72 hr together with linc-MD1 ([Figure 3](#fig3){ref-type="fig"}A). A parallel northern analysis shows that miR-133, which is low in the initial stages of differentiation, progressively increases, reaching maximum levels after 72 hr when both HuR and linc-MD1 are downregulated.

Since two isoforms contribute to the miR-133 pool (miR-133b and the two miR-133a members, a-1 and a-2), we initially tested, as a sensor for miR-133b production, the accumulation of 5′ cutoff products originating from Drosha cleavage ([Figure 3](#fig3){ref-type="fig"}B). To analyze these species, we treated nuclear RNA with polyA terminal transferase that was retrotranscribed with oligo-dT primers and amplified with oligonucleotides upstream of the Drosha cleavage site (see [Table S2](#app2){ref-type="sec"}; [Figure S3](#app2){ref-type="sec"}B). Quantification of the RT-PCR products indicated a continuous increase of their accumulation, opposite to the trend of linc-MD1 and HuR ([Figure 3](#fig3){ref-type="fig"}A). Therefore, after 72 hr of differentiation, a clear inverse correlation between Drosha cleavage and linc-MD1 production is observed, and this parallels the HuR decrease.

Modulation of HuR expression was used to test whether it had any direct effect on the alternative production of linc-MD1 and miR-133b. RNAi against HuR produced a consistent decrease in cytoplasmic linc-MD1 accumulation in parallel with a remarkable increase of 5′ cutoff products ([Figure 3](#fig3){ref-type="fig"}C). In order to demonstrate a direct effect on miR-133b processing, we set up specific conditions to distinguish miR-133a from miR-133b by LNA-based quantitative RT-PCR (qRT-PCR; [Figure S3](#app2){ref-type="sec"}C). We observed that upon HuR downregulation, the miR-133b/miR-133a ratio increased about 2-fold, paralleling the effect observed for 5′ cutoff products. To further confirm these data, we also performed small RNA-seq on C~2~C~12~ cells treated with HuR small interfering RNAs (siRNAs). The results again indicate a relative increase of miR-133b with respect to miR-133a ([Figure S3](#app2){ref-type="sec"}D; [Table S3](#mmc2){ref-type="supplementary-material"}). Altogether, these data show that HuR is able to trigger linc-MD1 formation and accumulation in the cytoplasm in a pathway alternative to miR-133b biogenesis; moreover, they indicate that this process is regulated during differentiation.

HuR overexpression was performed in HeLa cells, where HuR is less abundant in the nucleus and linc-MD1 is not expressed. [Figure S3](#app2){ref-type="sec"}F shows that although HuR overexpression represses miR-133b release from a transfected linc-MD1 coding plasmid (pMD1WT), it has no effect on the mutant pMD1*ΔHuR*, which lacks the HuR-binding site described in [Figure 2](#fig2){ref-type="fig"}F.

Since HuR was described to participate in RNA export to the cytoplasm, we tested whether the cytoplasmic levels of linc-MD1 were affected by leptomycin B, which is known to interfere specifically with HuR transport ([@bib9]). No change of cytoplasmic linc-MD1 was observed ([Figure S3](#app2){ref-type="sec"}E), excluding this possibility.

One obvious assumption to explain HuR activity was then the competition for Drosha cleavage. In vitro processing extracts were produced from HeLa cells treated with either scramble or anti-HuR siRNAs. [Figure S3](#app2){ref-type="sec"}H shows that pri-miR-133b displayed a very slight but reproducible increase of pre-miR-133b processing when HuR was downregulated by RNAi ([Figure S3](#app2){ref-type="sec"}G), indicating again the repressive effect of HuR on miR-133b biogenesis. It is important to underline that this very inefficient processing phenotype (for comparison, see the positive control pri-miR-9-2 in [Figure S3](#app2){ref-type="sec"}H), is likely to be due to the presence in pri-miR-133b of a 60-nt-long stem ([Figure S3](#app2){ref-type="sec"}I), which makes it a very poor microprocessor substrate ([@bib12]).

HuR Helps miRNA Recruitment in the Cytoplasm {#sec2.4}
--------------------------------------------

Since HuR was previously described to modulate miRNA-target recognition in the cytoplasm, we tested whether it could affect the sponging activity of linc-MD1. The effect of miR-135 overexpression in combination with HuR depletion was analyzed in C~2~C~12~ cells on the pRLuc-MD1-WT sensor construct and on its mutant derivative, pRLuc-MD1*-*Δ135, lacking the miR-135 MREs ([Figure 4](#fig4){ref-type="fig"}A, top). We chose to use miR-135 instead of miR-133 because it has two binding sites in two positions independently of HuR binding, and to exclude the superimposing negative effect of miR-133 on HuR synthesis (see [Figure 1](#fig1){ref-type="fig"}B). Moreover, since both pRLuc-MD1 constructs harbor a mutation that abolishes Drosha cleavage (see [@bib5]), we were able to exclude the nuclear activity of HuR and specifically analyze possible cytoplasmic effects. [Figure 4](#fig4){ref-type="fig"}A shows that with respect to pRLuc-MD-Δ135, the luciferase levels of Luc-MD1*-*WT decreased in the presence of endogenous levels of miR-135 (− samples, black bars). When RNAi against HuR was applied, a slight but reproducible increase of luciferase was observed for pRLuc-MD1-WT, but not for pRLuc-MD1-Δ135 (− samples, white bars). Moreover, increasing amounts of p135 further reduced pRLuc-MD1*-*WT luciferase activity (+ and ++, black bars), and this reduction was partially lessened when HuR expression was depleted by RNAi (white bars). Notably, the levels of luciferase mRNA paralleled the levels of luciferase activity, indicating that miRNA repression is also accompanied by RNA degradation ([Figure S4](#app2){ref-type="sec"}A). Along this line, we observed that the endogenous levels of linc-MD1 were upregulated when LNA against miR-135 was transfected into C~2~C~12~ cells ([Figure 4](#fig4){ref-type="fig"}B).

According to the ceRNA hypothesis, the effect of HuR on linc-MD1 levels and sponge activity should indirectly affect the circuitry controlled by linc-MD1. Therefore, the accumulation of the known components of the linc-MD1 circuitry ([@bib5]) was tested in conditions of HuR depletion. [Figure 4](#fig4){ref-type="fig"}C shows that upon RNAi of HuR, both Maml1 and Mef2C were downregulated. Since HuR also acts by stabilizing certain classes of transcripts, such as its own mRNA and Myogenin, we tested whether Maml1 and Mef2C mRNAs could be found in HuR IPs. Maml1 was completely absent and Mef2C was only present in traces (∼12-fold less than HuR mRNA; [Figure S4](#app2){ref-type="sec"}B), suggesting that their accumulation is more likely to be controlled by the linc-MD1 ceRNA circuitry than simply by a stabilizing effect of their mRNAs.

Altogether, these data indicate that HuR facilitates the linc-MD1-miRNA interaction, enhancing its sponge activity with effects on the ceRNA circuitry.

Discussion {#sec3}
==========

The commitment of precursor muscle cells to initiate and progress into the differentiation path relies on the temporally orderly expression of specific myogenic factors. The linc-MD1-regulated network, which was initially defined on the basis of transcriptional control, was recently enlarged when muscle-specific miRNAs ([@bib32]) and lncRNAs ([@bib5; @bib30]) came to the scene.

In particular, the miRNA sponge activity of linc-MD1 resulted in the upregulation of two myogenic factors, Maml1 and Mef2C. The expectation, according to the ceRNA hypothesis, is that a large number of coding and noncoding RNAs can crosstalk with each other through competition for common miRNAs ([@bib26]).

In this work, we identified the HuR protein as another component of the linc-MD1-regulated circuitry. We showed that HuR is repressed by miR-133, and that linc-MD1 alleviates this effect in early phases of differentiation.

HuR was particularly attractive because it is known to contribute in a relevant manner to muscle differentiation ([@bib29]); however, due to its many interactors and functions, a simple classification of its activity is still difficult to obtain. Transcriptome-wide analysis revealed that HuR interacts with many mRNAs, as well as with numerous noncoding RNAs, indicating its pleiotropic RNA-binding activity ([@bib19; @bib23]).

Besides describing HuR as a component of the linc-MD1 circuitry, we show that HuR binds linc-MD1 and favors its accumulation at the expense of miR-133b biogenesis, thus establishing a positive feedforward control. This regulatory circuitry is reinforced in the cytoplasm by the positive effect of HuR on miRNA recruitment on linc-MD1, thus contributing to its sponging activity.

Based on the inverse correlation between HuR levels and Drosha cleavage products, the most straightforward hypothesis to explain HuR's mode of action is that the two factors compete for the linc-MD1 substrate, as previously shown for the processing of tissue-specific miRNAs ([@bib15; @bib6]). We found that when HuR was downregulated, the levels of miR-133b and the 5′ cutoff products originating from Drosha cleavage indeed increased. Moreover, despite the inefficiency of the in vitro processing assays, we observed a slight but reproducible increase of pre-miR133b release when HuR was downregulated. The low efficiency of in vitro processing is likely due to the structure of pri-miR-133b, which is a very poor Drosha substrate and thus hampers the visualization of strong regulatory effects. Moreover, since Drosha is known to act cotranscriptionally ([@bib21; @bib2]), it is likely that the in vitro system does not allow proper reconstitution of the process.

Finally, the mapping of the HuR-binding site at the base of the pri-miR-133b stem loop corroborated the conclusion that HuR physically interferes with microprocessor activity.

The positive loop linking HuR and linc-MD1 operates in a specific window of time, finely controlling the relative abundance of the two factors. A possible trigger for exit from the positive HuR/linc-MD1 loop is the establishment of sustained miR-133 expression at later stages of differentiation. Notably, miR-133b, harbored in the linc-MD1 locus, contributes by only to a minor extent to the cellular miR-133 levels, which instead are mainly represented by the miR-133a-1 and miR-133a-2 species ([Figure S4](#app2){ref-type="sec"}C).

The miR-133 family is composed of three members clustered into bicistronic pairs with miR-1 and miR-206. The three clusters most likely arose from two genomic duplications on different chromosomes ([@bib13]; [Figure S4](#app2){ref-type="sec"}D). The miR-206/133b gene cluster is the most recent addition and it is only present in vertebrates, whereas miR-1 and miR-133a are both conserved in fly and worm. The origin of the miR-133b locus correlates with the increase in complexity of vertebrate skeletal muscle. In fact, fly and worm do not have satellite cells, nor do they possess different fiber types, such as slow-twitch and fast-twitch fibers, as found in vertebrate skeletal muscle. Therefore, the hypothesis that the three miR-133 loci have differentiated their activity to meet the unique regulatory demands of vertebrates is very attractive. Although the 133a-1 and 133a-2 loci would provide most of the functional miRNA molecules, the locus encoding for miR-133b and its host linc-MD1 transcript would have acquired more dedicated regulatory functions. It is possible to suggest that the role of linc-MD1 in fine-tuning the timing control of differentiation is critical only in organisms that require specific control of muscle regeneration or more specific muscle specializations.

Experimental Procedures {#sec4}
=======================

Cell Cultures and Treatments {#sec4.1}
----------------------------

C~2~C~12~ murine myoblasts were cultured and transfected as previously described [@bib3], with the exception that 0.5% fetal bovine serum was used in the DM. Transient transfection of plasmid, siRNA (QIAGEN; 40 nM final concentration), and LNA oligos (EXIQON; 100 nM final concentration) was carried out with the use of Lipofectamine-2000 (Invitrogen) according to the manufacturer's specifications. Human primary myoblasts were cultured according to [@bib4]). HeLa cells were cultured and transfected as previously described ([@bib21]).

RIP {#sec4.2}
---

RIP was performed by incubating 20 μg of antibody or isotypic IgGs to 30 μl of Protein A/G salmon sperm agarose beads (Millipore) for 2 hr at 4°C. C~2~C~12~ lysates were prepared with cells cultured for 2 days in DM with 100 μl of passive lysis buffer (PLB); 200 μg of each lysate was used for each RIP assay. Samples were precleared for 1 hr at 4°C with 30 μl of beads, and the supernatant was then resuspended in 600 μl of NT2 buffer and added to antibody-coated beads for 4 hr at 4°C. Beads were washed with NT2 buffer five times and split for protein (1/3) and RNA analysis (2/3). One-fifth of the input lysate was used as control. PLB and NT2 buffers were prepared according to [@bib27]).

Biotin-RNA Pull-Down Assay {#sec4.3}
--------------------------

A biotin-RNA pull-down assay was carried out by incubating 1.5 μg of biotinylated RNA antisense transcripts with 250 μg of cytoplasmic lysate prepared with Buffer A for 30 min at room temperature. Then 100 μl of Streptavidin MagneSphere paramagnetic particles (Promega) was saturated with 150 μg of tRNA and added to the extract for 15 min at room temperature. After three washings with the EMSA buffer, the bound RNA and protein complexes were eluted and subsequently analyzed by qRT-PCR and western blot, respectively. Biotinylated transcripts were obtained from PCR-generated templates (oligonucleotides are listed in [Table S2](#app2){ref-type="sec"}) by using the MAXIscript in vitro transcription system (Life Technologies). All buffer compositions are described in [@bib22].

Electrophoretic Mobility Shift Assay {#sec4.4}
------------------------------------

EMSA was carried out as described in [@bib17]) unless the incubation was performed at 25°C for 30 min. RNA substrates were prepared by in vitro transcription using T7 RNA polymerase (Promega) from PCR-amplified templates (oligonucleotides are listed in [Table S2](#app2){ref-type="sec"}) in the presence of \[α-^32^P\]UTP (Perkin-Elmer). Flag-HuR was purified by C~2~C~12~ cells transiently transfected with plasmid for HuR overexpression (kindly provided by G. Michlewsky), using anti-FlagM2 (Sigma) antibody and the Dynabeads Protein G Immunoprecipitation Kit (Invitrogen) according to the manufacturer's instructions.

RNA Analyses {#sec4.5}
------------

### Northern Blot and Quantitative Real-Time PCR {#sec4.5.1}

Total RNA from C~2~C~12~ cells was isolated as described in [@bib22]) and nuclear/cytoplasmic RNA fractionation was carried out using the Paris Kit (Ambion) according to the manufacturer's specifications. The northern blot assay was performed as described in [@bib3]). cDNA generation was carried out using the miScript Reverse Transcription Kit (QIAGEN). Real-time PCR detection of miRNAs and cutoff molecules was performed using the miScript SYBR-Green PCR Kit and DNA oligonucleotides (QIAGEN).

Protein Extraction and Western Blot {#sec4.6}
-----------------------------------

Total protein extract was obtained as described in [@bib18]) and nuclear/cytoplasmic fractionation was carried out by using the NE-Per Kit (Thermo Scientific-Pierce) according to the manufacturer's specifications. The immunoblots were incubated with the following antibodies: anti-HuR (sc-5261; Santa Cruz) or anti-Ago2 (01822021; Wako), anti-Mef2C (ab79436; Abcam), anti-Maml1 (A300-673a; BETHYL), anti-Hprt (sc-20975; Santa Cruz), and anti-Actinin (sc-15335, Santa Cruz). The densitometric analysis was performed using Image Lab software (Bio-Rad).

The miRNA predictions pipeline, luciferase reporter assays, plasmid descriptions, enzymatic assays, RNA-seq methods, and a complete list of all oligonucleotides used in this work are available in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4, Tables S1 and S2, and Supplemental Experimental ProceduresTable S3. Small RNA-Seq Analysis of Scramble and HuR siRNA-Treated C2C12 Cells at 2 Days of Differentiation, Related to Figure 3
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![linc-MD1 Regulates HuR Expression by Sponging miR-133\
(A) The short and long 3′ UTRs of HuR mRNA containing one or two miR-133 MREs were cloned downstream of the Renilla luciferase coding region (Luc-HuR*WT*) in parallel with mutant derivatives the lacking MREs (Luc-HuR*mut*). The position of the MREs is indicated.\
(B) Luciferase activity of short (upper panel) and long (lower panel) Luc-HuR*WT* transfected in C~2~C~12~ cells in the presence of control (LNA-Scr) or anti-miR-133 (LNA-133) LNA oligonucleotides.\
(C) Luciferase activity of short and long Luc-HuR*WT* and the mutant derivatives cotransfected with pMD1 or pMD1*mut* (corresponding to pMD1-ΔDrosha and pMD1-ΔDrosha-Δ133 described in [@bib5]) in C~2~C~12~ cells. The level of pMD1 and pMD1*mut* expression is shown in [Figure S1](#app2){ref-type="sec"}C. Luciferase activity was tested 2 days after the shift to DM. FLuc/RLuc RQ is shown with respect to a control sample set to a value of one. Data were derived from at least three independent experiments, error bars represent SE, and asterisk corresponds to two-tailed Student's t test p \< 0.05.\
(D) Schematic representation of the ceRNA circuitry linking linc-MD1, HuR, and miR-133.\
(E) RT-PCR (upper panels) and western (lower panels) analyses of linc-MD1 and HuR levels following linc-MD1 knockdown (RNAi -- siMD1) or overexpression (pMD1) in C~2~C~12~ cells at 2 days of differentiation. Control siRNAs (si-Scr) and empty vector (pCtrl) were used as controls together with HPRT mRNA and Actinin. Right panel: western blot of HuR levels at 2-day treatment in differentiation conditions with control (LNA-Scr) and anti-miR-133 (LNA-133) LNA oligonucleotides. Below each panel, relative quantifications derived from at least three independent experiments are indicated with respect to control samples set to a value of one.](gr1){#fig1}

![HuR Associates with linc-MD1\
(A) RIP was performed on cytoplasmic extracts from C~2~C~12~ cells and human myoblasts shifted to DM for 2 and 5 days, respectively. The extracts were incubated with anti-HuR (IP) or control antibodies (IgG). Beads-only were used as control (BO). The eluted RNA was analyzed by RT-PCR. IP efficiency was assessed by western blot (see [Figure S2](#app2){ref-type="sec"}A).\
(B) RIP was performed as in (A) by using anti-Ago2 antibodies. IP efficiency was assessed by western blot (see [Figure S2](#app2){ref-type="sec"}C).\
(C) Biotinylated antisense RNA complementary to the 3′ region of linc-MD1 was incubated with cytoplasmic extracts of C~2~C~12~ cells (2 days of DM). RNA pull-down was performed with streptavidin-linked beads (schematic representation in the top panel). Bottom panel: western blot of HuR, Ago2, and Actinin from input (Inp), specific probe-bound fraction (MD1 probe), beads-only (BO), and unspecific RNA probe (Control probe). The recovered linc-MD1 is shown in [Figure S2](#app2){ref-type="sec"}D (left panel). The graph shows the ratio of miR-133 and miR-135 between the fraction bound to the specific probe versus the control one. miR-31 and miR-206 are used as negative controls. Error bars represent SE. Pull-down efficiency was assessed by RT-PCR ([Figure S2](#app2){ref-type="sec"}E, left). Input represents 10% of the extract used for the pull-down. Extract from GM cells, where linc-MD1 is not expressed, was used as negative control ([Figure S2](#app2){ref-type="sec"}E, right).\
(D) EMSA using in vitro ^32^P-labeled transcripts and purified flag-HuR protein ([Figure S2](#app2){ref-type="sec"}F). The amounts of recombinant protein utilized are reported above the panels. Mock samples with 200 nM flag peptide were used as control. The right panel shows a schematic representation of the three linc-MD1 regions (MD1 5′, MD1-133b, and MD1 3′) that were tested for HUR binding. The 3′ UTR of MyoD mRNA was used as positive control. The arrows indicate the specific shifts in MD1-133b.\
(E) EMSA using in vitro ^32^P-labeled MD1-133b transcript and 200 nM of purified flag-HuR protein in the presence of specific (MD1-133b) and unspecific (tRNA) cold RNA competitors (from 10 to 100 molar excess).\
(F) Left panel: schematic representation of the pri-miR-133b structure. The sequence corresponding to the HuR putative binding site is indicated together with the nucleotide substitutions of the mutant derivative. Arrows indicate the Drosha cleavage sites. Right panel: EMSA of in vitro ^32^P-labeled 133b-SL*WT* and 133b-SL*mut* transcripts with purified flag-HuR protein. The amounts of recombinant protein utilized are reported above the panels. The arrow indicates the specific shift due to HuR binding.](gr2){#fig2}

![Effects of HuR on linc-MD1 and miR-133b\
(A) Proteins and RNAs were extracted from C~2~C~12~ cells in GM or DM for the indicated hours. HuR was analyzed by western blot (WB), linc-MD1 and 5′ cutoff products were analyzed by RT-PCR, and miR-133 was analyzed by northern blot (NB). Hprt, U6 small nuclear RNA (snRNA), and 5SRNA were used as controls.\
(B) Schematic representation of linc-MD1, pre-miR-133b, and 5′ and 3′ cutoff products originating from Drosha cleavage (see also [Figure S3](#app2){ref-type="sec"}B).\
(C) Left panel: WB of HuR in C~2~C~12~ cells (day 2 of DM) upon treatment with either scramble (si-Scr) or anti-HuR (si-HuR) siRNAs. Actinin was used as control. Below each panel, relative quantifications derived from at least three independent experiments are indicated with respect to control samples set to a value of one. Right panel: bar graphs showing linc-MD1, 5′ cutoff, and miR-133b/miR-133a levels. Linc-MD1 was measured by RT-PCR in nuclear (NUC) and cytoplasmic (CYT) fractions of cells treated as in the left panel, and 5′ cutoff products were analyzed only in the nuclear fraction. Linc-MD1 and 5′ cutoff were normalized on HPRT mRNA and U6 snRNA, respectively. A schematic representation of the oligonucleotides used is provided in [Figure S3](#app2){ref-type="sec"}B. miRNA relative levels were measured by LNA-based quantitative PCR detection (see also [Figure S3](#app2){ref-type="sec"}C). Data were derived from at least three independent experiments, error bars represent SE, and the asterisk corresponds to two-tailed Student's t test p \< 0.05.](gr3){#fig3}

![HuR Regulates linc-MD1 ceRNA Activity\
(A) Upper panel: pRLuc-MD1-WT and Δ135 constructs carrying the linc-MD1 sequence downstream to the Renilla luciferase open reading frame ([@bib5]). The two miR-135 MREs, which are deleted in the Δ135 construct, are indicated. Lower panel: differentiating C~2~C~12~ cells were treated with scramble (si-Scr, black bars) or anti-HuR (si-HuR, white bars) siRNAs and transfected with RLuc-MD1-WT and Δ135, combined with empty vector (−) or increasing amounts of miR-135 coding plasmid (p-135). Luciferase activity was measured as RLuc/FLuc RQ after 48 hr. RNA from the "+" experiment was also analyzed for relative luciferase mRNA levels (see [Figure S4](#app2){ref-type="sec"}A). Data were derived from at least three independent experiments, error bars represent SE, and the asterisk corresponds to two-tailed Student's t test p \< 0.05.\
(B) RT-PCR analysis performed on linc-MD1 RNA in conditions of LNA-mediated miR-135 inhibition (LNA-135) with respect to control (LNA-Scr).\
(C) Western blot analysis of HuR, Maml1 and Mef2C performed on differentiating C~2~C~12~ cells treated with scramble (si-Scr) or anti-HuR (si-HuR) siRNAs.\
(D) Schematic representation of the positive feedforward control loop linking linc-MD1, miR-133, and HuR in early phases of muscle differentiation. The exit from the circuitry is obtained through miR-133 upregulation, mainly from the two unrelated miR-133a-1 and miR-133a-2 coding loci ([Figure S4](#app2){ref-type="sec"}D).](gr4){#fig4}
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